The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

Chen said that while patients with this type of breast cancer generally receive either adjuvant taxane-based regimens or taxane- and anthracycline-based regimens, there is limited data to guide ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...

Until recently, the treatment of metastatic castration-resistant prostate cancer (mCRPC) relied exclusively on hormonal therapies and taxane chemotherapy. The advent of modern molecular profiling ...